(Q33961795)

30 July 2017

1 reference

title

Development of resistance and perspectives for future therapies against hepatitis B infections: lessons to be learned from HIV. (English)

1 reference

30 July 2017

Deres K

1

1 reference

30 July 2017

Rübsamen-Waigmann H

series ordinal

2

1 reference

30 July 2017

publication date

1 January 1999

1 reference

30 July 2017

1 reference

30 July 2017

volume

27 Suppl 2

1 reference

30 July 2017

page(s)

S45-51

1 reference

Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-beta-L-2',3'-dideoxy-3'-thiacytidine

30 July 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF02561672

Postliver transplant allograft reinfection with a lamivudine-resistant strain of hepatitis B virus: long-term follow-up

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF02561672

Functional analysis of mutations conferring lamivudine resistance on hepatitis B virus

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF02561672

Importance of perinatal versus horizontal transmission of hepatitis B virus infection in China

21 January 2018

1 reference

12 December 2020

FDA advised to license three anti-HIV agents

1 reference

12 December 2020

Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans

1 reference

12 December 2020

Analysis of hepatitis B virus quasispecies changes during emergence and reversion of lamivudine resistance in liver transplantation.

1 reference

12 December 2020

Effect of beta-enantiomeric and racemic nucleoside analogues on mitochondrial functions in HepG2 cells. Implications for predicting drug hepatotoxicity

1 reference

12 December 2020

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

12 December 2020

High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation

1 reference

12 December 2020

Experience with lamivudine against hepatitis B virus

1 reference

12 December 2020

Therapy of viral hepatitis

1 reference

12 December 2020

Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives

1 reference

12 December 2020

Incidence of hepatitis B virus infection in the United States, 1976-1994: estimates from the National Health and Nutrition Examination Surveys

1 reference

12 December 2020

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

1 reference

12 December 2020

The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response.

1 reference

12 December 2020

A pilot study of steroid withdrawal followed by oral acyclovir in the treatment of chronic type B hepatitis

1 reference

12 December 2020

Hepatitis B virus immunopathogenesis

1 reference

12 December 2020

NIH panel report of 'no flaws' in FIAU trial at variance with FDA report, new probe planned.

1 reference

12 December 2020

NIH, PDA seek lessons from hepatitis B drug trial deaths

1 reference

12 December 2020

Current status of anti-HBV chemotherapy

1 reference

12 December 2020

'EUROHEP' consensus report on the management of liver transplantation for hepatitis B virus infection. European Concerted Action on Viral Hepatitis.

1 reference

12 December 2020

Therapy of chronic hepatitis B with a 6-month course of ribavirin.

1 reference

12 December 2020

Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver

1 reference

12 December 2020

Advances in the treatment of chronic hepatitis B virus infection.

1 reference

12 December 2020

Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo

1 reference

12 December 2020

Ganciclovir treatment of hepatitis B virus infection in liver transplant recipients

1 reference

12 December 2020

A double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection

1 reference

12 December 2020

Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment

1 reference

12 December 2020

Diagnostic markers of viral hepatitis B and C.

1 reference

12 December 2020

HBV viral load within subpopulations of peripheral blood mononuclear cells in HBV infection using limiting dilution PCR

1 reference

12 December 2020

Treatment of chronic hepatitis B with interferon: experience in western countries

1 reference

12 December 2020

Randomized controlled trial of adenine arabinoside monophosphate for chronic type B hepatitis

1 reference

12 December 2020

The M539V polymerase variant of human hepatitis B virus demonstrates resistance to 2'-deoxy-3'-thiacytidine and a reduced ability to synthesize viral DNA

1 reference

12 December 2020

Combination alpha-interferon and lamivudine therapy for alpha-interferon-resistant chronic hepatitis B infection: results of a pilot study

1 reference

12 December 2020

Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance

1 reference

12 December 2020

Ganciclovir treatment of active hepatitis B virus infection in a heart transplant patient

1 reference

12 December 2020

Therapeutic vaccination with p24-VLP and zidovudine augments HIV-specific cytotoxic T lymphocyte activity in asymptomatic HIV-infected individuals

1 reference

12 December 2020

Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro

1 reference

12 December 2020

2',3'-dideoxy-beta-L-5-fluorocytidine inhibits duck hepatitis B virus reverse transcription and suppresses viral DNA synthesis in hepatocytes, both in vitro and in vivo

1 reference

12 December 2020

Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy

1 reference

12 December 2020

Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation

1 reference

12 December 2020

The immunopathogenesis of HBV infection

1 reference

12 December 2020

The hepatitis B virus M539V polymerase variation responsible for 3TC resistance also confers cross-resistance to other nucleoside analogues.

1 reference

12 December 2020

A preliminary trial of lamivudine for chronic hepatitis B infection

1 reference

12 December 2020

World-wide epidemiology of hepatitis B

1 reference

12 December 2020

Sensitivity of L-(-)2,3-dideoxythiacytidine resistant hepatitis B virus to other antiviral nucleoside analogues

1 reference

12 December 2020

Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine

1 reference

12 December 2020

YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection

1 reference

12 December 2020

The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss.

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF02561672

1 reference

Dimensions Publication ID

30 July 2017

1024202123

0 references

1 reference